马来酸阿伐曲泊帕片avatrombopag maleate 20mg

Avatrombopag is a small-molecule thrombopoietin receptor (c-MPL) agonist that increases platelet count without activating platelets, thereby reducing the need for blood transfusion. Its mechanism of action is to stimulate the body to produce more platelets. Currently, it is used to treat thrombocytopenia in patients with chronic liver disease. It can also be used for thrombocytopenia in patients with chronic immune thrombocytopenia (a persistent condition characterized by abnormally low platelet count in the blood, which may lead to abnormal bruising or bleeding).

For the treatment of thrombocytopenia (low platelet count) in adult patients with chronic liver disease who are scheduled to undergo surgery.

20 mg per tablet; 30 tablets per box.

Store at 20°C to 25°C (68°F to 77°F). Short-term excursions between 15°C and 30°C (59°F and 86°F) are permitted for transportation.

Avatrombopag is an oral tablet. For thrombocytopenia in patients with chronic liver disease scheduled for surgery Initiate administration 10 to 13 days before surgery, once daily for a total of 5 days. For thrombocytopenia in patients with immune thrombocytopenia (ITP) Administer according to the physician’s instructions, usually once daily with food.

Avatrombopag is an orally bioavailable small-molecule thrombopoietin (TPO) receptor agonist that stimulates the proliferation and differentiation of megakaryocytes from bone marrow progenitors, leading to increased platelet production. Avatrombopag does not compete with thrombopoietin for binding to the TPO receptor, and has an additive pharmacological effect with TPO on platelet production. As a thrombopoietin receptor (TPOR) agonist, it has potential megakaryopoiesis-stimulating activity. After administration, avatrombopag binds to and activates the thrombopoietin receptor (TPOR), which can induce the proliferation and differentiation of megakaryocytes from bone marrow progenitors. This process increases platelet production and may help prevent chemotherapy-induced thrombocytopenia. TPOR is classified as a member of the cytokine receptor and hematopoietin receptor superfamily.

Common Adverse Reactions Extreme fatigue, headache, nosebleeds or gum bleeding, arthralgia, etc. Severe Adverse Reactions Swelling, pain, redness of hands, feet or legs; shortness of breath, fever, cough, chest pain or rapid heartbeat, stomach pain, etc.